Darutigenol links gut microbial proline production to colitis improvement in mice
Published in Biology, Drugs development & discovery, Immunology, Journals.
Published October 29, 2026.
A preclinical study links the anti-inflammatory effects of darutigenol to gut microbial metabolism. Li and colleagues published the findings today in Nature Communications.
Using male mice with experimental colitis, the researchers combined multi-omics analyses with fecal microbiota transplantation experiments to investigate the compound’s effects. The benefit depended on the gut microbiota.
The proposed pathway involves reduced expression of the host enzyme IDO1, expansion of Akkermansia muciniphila and increased proline synthesis. Supplementing proline separately also alleviated colitis in mice, alongside reduced IL-17 pathway signaling.
The work suggests that a compound with limited oral bioavailability can exert effects through interactions among host pathways, microbes and microbial metabolites. This provides a mechanistic direction for further drug-development research.
The findings remain limited to experimental systems, including male mice. They do not establish darutigenol, proline supplementation or an Akkermansia product as an effective treatment for inflammatory bowel disease in people. Clinical efficacy, dosing and safety require investigation.
Source: Li et al., Nature Communications. Published October 29, 2026. DOI: 10.1038/s41467-026-78308-z.